Benzofuran compounds as sting agonists

1 . A compound formula

wherein

A is a pyrazinyl group, a pyrimidinyl group, a pyridinyl group, a pyrazole-pyrimidinyl group, an imidazo-pyridazinyl group, a thiazolo-pyrdinyl group, imidazo-pyridinyl group or a naphthyridinyl group, each of said groups substituted with 0-4 R 2 groups,

X is O,

R 1 is hydrogen, CD 3 , CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, halo C 1-3 alkyl, aryl C 1-3 alkyl, hydroxy C 1-4 alkyl, halo C 1-3 alkoxy, NHR′, 4-10 membered heterocycle or aryl, all of said alkyl, cycloalkyl, heterocyclyl or aryl groups substituted with 0-4 R 1a ,

R 1a is halogen, CN, C 1-4 alkyl, halo C 1-3 alkyl, 4-10 membered heterocycle or aryl, all of said alkyl, heterocyclyl or aryl groups substituted with 0-2 R 1b ,

R 1b is halogen or C 1-4 alkyl,

R′ is hydrogen, OH, C 1-3 alkoxy or C 1-3 alkyl;

R 2 is, independently at each occurrence, hydrogen, halogen, CN, OH, COOH, C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, halo C 1-3 alkyl, hydroxy C 1-4 alkyl, halo C 1-3 alkoxy, NHR′, 4-10 membered heterocycle or aryl, all of said alkyl, heterocyclyl or aryl groups substituted with 0-2 R 2a ,

R 2a is halogen,

R 5 is hydrogen, halogen, CF 3 , C 1-6 alkyl, C 1-6 alkoxy or C 1-6 alkenyl,

R 6 is hydrogen, halogen, OH, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkenyl, CN or C 3-6 cycloalkyl

n is 0, 1, 2 or 3,

or a pharmaceutically acceptable salt thereof.

2 . A compound of formula

wherein A is

substituted with 0-4 R 2 groups,

X is O, S or NH,

R 1 is hydrogen, CD 3 , CF 3 , OH, C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, halo C 1-3 alkyl, aryl C 1-3 alkyl, hydroxy C 1-4 alkyl, halo C 1-3 alkoxy, NHR′, 4-10 membered heterocycle or aryl, all of said alkyl, cycloalkyl, heterocyclyl or aryl groups substituted with 0-4 R 1 ª, with the proviso that R 1 is OH only when X is NH;

R 1a is halogen, CN, C 1-4 alkyl, halo C 1-3 alkyl, 4-10 membered heterocycle or aryl, all of said alkyl, heterocyclyl or aryl groups substituted with 0-2 R 1b ,

R 1b is halogen or C 1-4 alkyl,

R′ is hydrogen, OH, C 1-3 alkoxy or C 1-3 alkyl;

R 2 is, independently at each occurrence, hydrogen, halogen, CN, OH, COOH, C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, halo C 1-3 alkyl, hydroxy C 1-4 alkyl, halo C 1-3 alkoxy, NHR′, 4-10 membered heterocycle or aryl, all of said alkyl, heterocyclyl or aryl groups substituted with 0-2 R 2a ,

R 2a is halogen or R 1a is halogen,

R 5 is hydrogen, halogen, CF 3 , C 1-6 alkyl, C 1-6 alkoxy or C 1-6 alkenyl,

R 6 is hydrogen, halogen, OH, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkenyl, CN or C 3-6 cycloalkyl

n is 0, 1, 2 or 3,

or a pharmaceutically acceptable salt thereof.

3 . The compound according to claim 2 of the formula

wherein A is

substituted with 0-4 R 2 groups,

X is O,

R 1 is hydrogen, CD 3 , CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl or halo C 1-3 alkyl, all of said alkyl groups substituted with 0-4 R 1a ;

R 1a is halogen;

R 2 is, independently at each occurrence, hydrogen, halogen, CN, OH, COOH, C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, halo C 1-3 alkyl, hydroxy C 1-4 alkyl, halo C 1-3 alkoxy, NHR′, 4-10 membered heterocycle or aryl, all of said alkyl, heterocyclyl or aryl groups substituted with 0-2 R 2a ,

R 2a is halogen or R 1a is halogen,

R 5 is hydrogen, halogen, CF 3 , C 1-6 alkyl, C 1-6 alkoxy or C 1-6 alkenyl;

R 6 is hydrogen, halogen, OH, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkenyl, CN or C 3-6 cycloalkyl

n is 0, 1, 2 or 3,

or a pharmaceutically acceptable salt thereof.

4 . A compound selected from

Tert-butyl 3-((5-chloro-2-((pyrazolo[1,5-a]pyrimidine-3-carboxamido)methyl)benzofuran-7-carbonyl)oxy)azetidine-1-carboxylate, (247)

Acetoxymethyl 5-chloro-2-((7yrazole[1,5-a]pyrimidine-3-carboxamido)methyl)benzofuran-7-carboxylate, (259)

((Ethoxycarbonyl)oxy)methyl 5-chloro-2-((pyrazolo[1,5-a]pyrimidine-3-carboxamido)methyl)benzofuran-7-carboxylate, (260),

1-((Ethoxycarbonyl)oxy)ethyl 5-chloro-2-((pyrazolo[1,5-a]pyrimidine-3-carboxamido)methyl)benzofuran-7-carboxylate, (261)

1-Ethoxy-2,2-difluoroethyl 5-fluoro-2-((pyrazolo[1,5-a]pyrimidine-3-carboxamido)methyl)benzofuran-7-carboxylate, (323,324)

S-(2-(Trimethylsilyl)ethyl) 3-chloro-5-fluoro-2-((pyrazolo[1,5-a]pyrimidine-3-carboxamido)methyl)benzofuran-7-carbothioate, (392)

S-(2-(Trimethylsilyl)ethyl) (S)-5-fluoro-2-(1-(pyrazolo[1,5-a]pyrimidine-3-carboxamido) ethyl)benzofuran-7-carbothioate (398)

S-(2-(Trimethylsilyl)ethyl) (S)-5-chloro-2-(1-(pyrazolo[1,5-a]pyrimidine-3-carboxamido) ethyl)benzofuran-7-carbothioate (400)

N-((5-Chloro-7-(1H-tetrazol-5-yl)benzofuran-2-yl) methyl) pyrazolo[1,5-a]pyrimidine-3-carboxamide (409),

N-((5-Chloro-7-(1H-tetrazol-5-yl)benzofuran-2-yl)methyl)-1,6-naphthyridine-8-carboxamide (410), or

a pharmaceutically acceptable salt thereof.

5 . A pharmaceutical composition comprising a compound according to claim 4 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.

6 . A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.

7 . A method of treating diseases and conditions in which the modulation of STING is indicated in a subject in need thereof which comprises administering a therapeutically effective amount of compound according to claim 1 or a pharmaceutically acceptable salt thereof.

8 . A method of treating cancer comprising administering a therapeutically effective amount of one or more compounds according to claim 2 or a pharmaceutically acceptable salt thereof.

9 . The method of claim 8 wherein the cancer is small cell lung cancer, non-small cell lung cancer, colorectal cancer, melanoma, renal cell carcinoma, head and neck cancer, Hodgkin's lymphoma, bladder cancer, esophageal carcinoma, gastric carcinoma, ovarian carcinoma, cervical carcinoma, pancreatic carcinoma, prostate carcinoma, breast cancers, urinary carcinoma, brain tumors such as glioblastoma, non-Hodgkin's lymphoma, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), hepatocellular carcinoma, multiple myeloma, gastrointestinal stromal tumors, mesothelioma, and other solid tumors or other hematological cancers.

10 . The method of claim 9 wherein the cancer is small cell lung cancer, non-small cell lung cancer, colorectal cancer, melanoma, renal cell carcinoma, head and neck cancer, Hodgkin's lymphoma or bladder cancer.

11 . A method for treating cancer in a subject in need thereof, comprising administering an effective amount of a compound, according to claim 2 , or a pharmaceutically acceptable salt thereof,

in combination with the administration of a therapeutically effective amount of one or more immuno-oncology agents.

12 . A compound selected from

N-((5-chloro-7,9-dioxo-8,9-dihydro-7H-benzofuro[7,6-e][1,3]oxazin-2-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide,

N-((5-Chloro-7-(1H-tetrazol-5-yl)benzofuran-2-yl)methyl) pyrazolo[1,5-a]pyrimidine-3-carboxamide,

N-((5-Chloro-7-(1H-tetrazol-5-yl)benzofuran-2-yl)methyl)-1,6-naphthyridine-8-carboxamide,

1-methyl-2-((pyrazolo[1,5-a]pyrimidine-3-carboxamido)methyl)-1H-benzo[d]imidazole-4-carboxylic acid,

or a pharmaceutically acceptable salt thereof.